20. 副腎白質ジストロフィー Adrenoleukodystrophy Clinical trials / Disease details
臨床試験数 : 53 / 薬物数 : 88 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02961803 (ClinicalTrials.gov) | October 2014 | 9/11/2016 | MD1003-AMN MD1003 in Adrenomyeloneuropathy | MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study | Adrenomyeloneuropathy;Adrenoleukodystrophy;AMN | Drug: MD1003 100 mg capsule;Drug: Placebo | MedDay Pharmaceuticals SA | NULL | Completed | 18 Years | 60 Years | Male | 67 | Phase 2/Phase 3 | France;Germany;Spain |
| 2 | EUCTR2014-000698-38-ES (EUCTR) | 13/08/2014 | 13/06/2014 | MD1003 IN ADRENOMYELONEUROPATHY | MD1003 IN ADRENOMYELONEUROPATHY: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY - MD1003-AMN | Adrenomyeloneuropathy MedDRA version: 17.0;Level: LLT;Classification code 10069075;Term: Adrenomyeloneuropathy without cerebral involvement;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY SAS | NULL | Not Recruiting | Female: no Male: yes | 60 | Phase 2;Phase 3 | Spain |